| Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
|---|
| Phenindamine | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | | Phenindamine | hsa00040 | Pentose and glucuronate interconversions | 4.00E-02 | 1 | P15121 | AKR1B1 | More | | | Phenindamine | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | | | Phenindamine | hsa00190 | Oxidative phosphorylation | 1.03E-05 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | | | Phenindamine | hsa00220 | Arginine biosynthesis | 1.97E-02 | 2 | P15104, P49448 | GLUL, GLUD2 | More | | | Phenindamine | hsa00250 | Alanine, aspartate and glutamate metabolism | 1.97E-02 | 2 | P49448, P15104 | GLUD2, GLUL | More | | | Phenindamine | hsa00512 | Mucin type O-glycan biosynthesis | 3.78E-02 | 2 | O95395, Q8N4A0 | GCNT3, GALNT4 | More | | | Phenindamine | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 3.43E-02 | 1 | Q9NY97 | B3GNT2 | More | | | Phenindamine | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | | | Phenindamine | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | | Phenindamine | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | | Phenindamine | hsa00640 | Propanoate metabolism | 3.83E-02 | 2 | Q02252, Q9P2R7 | ALDH6A1, SUCLA2 | More | | | Phenindamine | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | | | Phenindamine | hsa00790 | Folate biosynthesis | 2.02E-02 | 1 | P15121 | AKR1B1 | More | | | Phenindamine | hsa00910 | Nitrogen metabolism | 1.97E-02 | 2 | P15104, P49448 | GLUL, GLUD2 | More | | | Phenindamine | hsa00970 | Aminoacyl-tRNA biosynthesis | 2.24E-03 | 3 | O95363, P14868, Q15046 | FARS2, DARS, KARS | More | | | Phenindamine | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 6.38E-04 | 3 | P78417, P09211, P11712 | GSTO1, GSTP1, CYP2C9 | More | | | Phenindamine | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | | Phenindamine | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | | Phenindamine | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | | | Phenindamine | hsa01523 | Antifolate resistance | 3.80E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | | | Phenindamine | hsa02010 | ABC transporters | 2.17E-03 | 3 | P45844, P08183, Q8IZY2 | ABCG1, ABCB1, ABCA7 | More | | | Phenindamine | hsa03010 | Ribosome | 2.25E-04 | 5 | P40429, Q07020, P27635, P05386, P62249 | RPL13A, RPL18, RPL10, RPLP1, RPS16 | More | | | Phenindamine | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | | Phenindamine | hsa03040 | Spliceosome | 1.28E-05 | 13 | O43143, O60508, P08579, P26368, Q13595, Q07955, Q01130, P84103, Q13243, P11142, Q9Y2W2, O43447, O75643 | DHX15, CDC40, SNRPB2, U2AF2, TRA2A, SFRS1, SFRS2, SFRS3, SFRS5, HSPA8, WBP11, PPIH, ASCC3L1 | More | | | Phenindamine | hsa03050 | Proteasome | 1.21E-02 | 1 | P28074 | PSMB5 | More | | | Phenindamine | hsa03450 | Non-homologous end-joining | 4.21E-02 | 1 | P13010 | XRCC5 | More | | | Phenindamine | hsa04010 | MAPK signaling pathway | 1.53E-02 | 2 | Q9H2K8, Q12933 | TAOK3, TRAF2 | More | | | Phenindamine | hsa04014 | Ras signaling pathway | 2.36E-02 | 8 | P42338, P20827, P49767, Q13009, Q7LDG7, P63218, P50151, P19174 | PIK3CB, EFNA1, VEGFC, TIAM1, RASGRP2, GNG5, GNG10, PLCG1 | More | | | Phenindamine | hsa04015 | Rap1 signaling pathway | 1.79E-02 | 8 | P20827, P49767, Q96FS4, P11215, Q13009, Q7LDG7, P42338, P19174 | EFNA1, VEGFC, SIPA1, ITGAM, TIAM1, RASGRP2, PIK3CB, PLCG1 | More | | | Phenindamine | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 4.48E-02 | 5 | P09341, P19875, P25024, P25025, P14784 | CXCL1, CXCL2, CXCR1, CXCR2, IL2RB | More | | | Phenindamine | hsa04062 | Chemokine signaling pathway | 5.65E-04 | 14 | P25024, P25025, P09341, P19875, P09769, P07948, P42338, P19174, P63218, P50151, P43250, Q7LDG7, Q13009, Q8WYR1 | CXCR1, CXCR2, CXCL1, CXCL2, FGR, LYN, PIK3CB, PLCG1, GNG5, GNG10, GRK6, RASGRP2, TIAM1, PIK3R5 | More | | | Phenindamine | hsa04064 | NF-kappa B signaling pathway | 2.49E-03 | 13 | P10415, Q13489, P14778, P29965, P19174, Q04759, Q9UDY8, P06239, Q8WV28, Q13315, P09341, P19875, Q06643 | BCL2, BIRC3, IL1R1, CD40LG, PLCG1, PRKCQ, MALT1, LCK, BLNK, ATM, CXCL1, CXCL2, LTB | More | | | Phenindamine | hsa04070 | Phosphatidylinositol signaling system | 3.47E-02 | 4 | P0DP23, Q14643, P23743, P17252 | CALM1, ITPR1, DGKA, PRKCA | More | | | Phenindamine | hsa04071 | Sphingolipid signaling pathway | 1.65E-04 | 9 | P17252, P21453, Q9H228, P01375, Q13362, Q9BX95, P10415, Q12933, Q02156 | PRKCA, S1PR1, EDG8, TNF, PPP2R5C, SGPP1, BCL2, TRAF2, PRKCE | More | | | Phenindamine | hsa04072 | Phospholipase D signaling pathway | 4.48E-02 | 5 | P42338, P43657, P25024, P25025, P19174 | PIK3CB, P2RY5, CXCR1, CXCR2, PLCG1 | More | | | Phenindamine | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | | | Phenindamine | hsa04110 | Cell cycle | 6.80E-03 | 6 | P06493, O75293, P30304, P33981, P42773, P01106 | CDK1, GADD45B, CDC25A, TTK, CDKN2C, MYC | More | | | Phenindamine | hsa04114 | Oocyte meiosis | 1.33E-02 | 4 | P51812, Q02750, P16298, Q17RY0 | RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | | | Phenindamine | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | | Phenindamine | hsa04145 | Phagosome | 1.59E-03 | 7 | Q15080, P14598, Q13509, P68371, Q13488, O60603, P13765 | NCF4, NCF1, TUBB3, TUBB2C, TCIRG1, TLR2, HLA-DOB | More | | | Phenindamine | hsa04150 | mTOR signaling pathway | 3.60E-02 | 3 | Q02750, Q9NQL2, P51812 | MAP2K1, RRAGD, RPS6KA3 | More | | | Phenindamine | hsa04151 | PI3K-Akt signaling pathway | 7.37E-04 | 23 | P42338, P43657, P25116, P09603, P20827, P49767, Q9GZP0, Q13362, P08238, Q8WYR1, P62873, P63218, P50151, P13612, P16144, O15335, Q13751, O60603, P14784, P01568, P10415, P17252, P30281 | PIK3CB, P2RY5, F2R, CSF1, EFNA1, VEGFC, PDGFD, PPP2R5C, HSP90AB1, PIK3R5, GNB1, GNG5, GNG10, ITGA4, ITGB4, CHAD, LAMB3, TLR2, IL2RB, IFNA21, BCL2, PRKCA, CCND3 | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | 0.777 | | P61088 | UBE2N | Ubiquitin-conjugating enzyme E2 N | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | 0.702 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | -0.735 | | P17252 | PRKCA | Protein kinase C alpha type | P25116 | F2R | Proteinase-activated receptor 1 | 0.857 | | P61088 | UBE2N | Ubiquitin-conjugating enzyme E2 N | P09603 | CSF1 | Macrophage colony-stimulating factor 1 | -0.789 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P20827 | EFNA1 | Ephrin-A1 | 0.715 | | P17252 | PRKCA | Protein kinase C alpha type | P49767 | VEGFC | Vascular endothelial growth factor C | 0.719 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P49767 | VEGFC | Vascular endothelial growth factor C | 0.743 | | P61088 | UBE2N | Ubiquitin-conjugating enzyme E2 N | Q9GZP0 | PDGFD | Platelet-derived growth factor D | 0.736 | | P17252 | PRKCA | Protein kinase C alpha type | Q13362 | PPP2R5C | Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform | 0.745 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | -0.823 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q8WYR1 | PIK3R5 | Phosphoinositide 3-kinase regulatory subunit 5 | 0.752 | | P17252 | PRKCA | Protein kinase C alpha type | P62873 | GNB1 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | -0.852 | | P61088 | UBE2N | Ubiquitin-conjugating enzyme E2 N | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | -0.844 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.941 | | P61088 | UBE2N | Ubiquitin-conjugating enzyme E2 N | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | -0.902 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.948 | | P61088 | UBE2N | Ubiquitin-conjugating enzyme E2 N | P13612 | ITGA4 | Integrin alpha-4 | 0.77 | | P17252 | PRKCA | Protein kinase C alpha type | P16144 | ITGB4 | Integrin beta-4 | 0.755 | | P61088 | UBE2N | Ubiquitin-conjugating enzyme E2 N | O15335 | CHAD | Chondroadherin | -0.729 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O15335 | CHAD | Chondroadherin | 0.795 | | P61088 | UBE2N | Ubiquitin-conjugating enzyme E2 N | Q13751 | LAMB3 | Laminin subunit beta-3 | -0.794 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13751 | LAMB3 | Laminin subunit beta-3 | 0.844 | | P17252 | PRKCA | Protein kinase C alpha type | O60603 | TLR2 | Toll-like receptor 2 | -0.716 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.835 | | P17252 | PRKCA | Protein kinase C alpha type | P01568 | IFNA21 | Interferon alpha-21 | 0.733 | | P17252 | PRKCA | Protein kinase C alpha type | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.844 | | P17252 | PRKCA | Protein kinase C alpha type | P17252 | PRKCA | Protein kinase C alpha type | 1 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P30281 | CCND3 | G1/S-specific cyclin-D3 | 0.743 |
| | Phenindamine | hsa04213 | Longevity regulating pathway - multiple species | 3.85E-02 | 4 | P42338, Q9Y4H2, P11142, Q13547 | PIK3CB, IRS2, HSPA8, HDAC1 | More | | | Phenindamine | hsa04215 | Apoptosis - multiple species | 1.56E-02 | 2 | Q13489, P10415 | BIRC3, BCL2 | More | | | Phenindamine | hsa04217 | Necroptosis | 7.46E-06 | 13 | P01375, P01568, P48023, Q13489, P42224, Q14765, P08238, Q6FI13, Q99878, Q93077, P10415, O43633, Q08752 | TNF, IFNA21, FASLG, BIRC3, STAT1, STAT4, HSP90AB1, H2AC18; H2AC19, H2AC14, HIST1H2AC, BCL2, CHMP2A, PPID | More | | | Phenindamine | hsa04218 | Cellular senescence | 4.79E-02 | 4 | P01106, O75293, P30304, P06493 | MYC, GADD45B, CDC25A, CDK1 | More | | | Phenindamine | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.31E-03 | 8 | P09493, P07550, P22694, P18848, Q13362, P0DP23, P17252, P10415 | TPM1, ADRB2, PRKACB, ATF4, PPP2R5C, CALM1, PRKCA, BCL2 | More | | | Phenindamine | hsa04360 | Axon guidance | 4.04E-02 | 6 | P16333, P20827, O95631, P42338, P07332, P19174 | NCK1, EFNA1, NTN1, PIK3CB, FES, PLCG1 | More | | | Phenindamine | hsa04370 | VEGF signaling pathway | 2.68E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | | | Phenindamine | hsa04371 | Apelin signaling pathway | 1.00E-02 | 7 | P63218, P50151, Q8WYR1, Q14814, Q14344, Q13485, P84022 | GNG5, GNG10, PIK3R5, MEF2D, GNA13, SMAD4, SMAD3 | More | | | Phenindamine | hsa04390 | Hippo signaling pathway | 2.08E-02 | 3 | P84022, Q13485, Q13489 | SMAD3, SMAD4, BIRC3 | More | | | Phenindamine | hsa04512 | ECM-receptor interaction | 4.41E-02 | 3 | Q13751, P13612, O15335 | LAMB3, ITGA4, CHAD | More | | | Phenindamine | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | | Phenindamine | hsa04540 | Gap junction | 1.29E-02 | 4 | P17252, Q13509, P68371, Q14643 | PRKCA, TUBB3, TUBB2C, ITPR1 | More | | | Phenindamine | hsa04610 | Complement and coagulation cascades | 2.33E-03 | 1 | P0C0L4 | C4A | More | | | Phenindamine | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | | | Phenindamine | hsa04613 | Neutrophil extracellular trap formation | 3.41E-04 | 14 | P17252, O60603, P08246, P04908, Q6FI13, Q93077, P62807, O60814, P68431, P14598, Q15080, P21462, O43315, Q16539 | PRKCA, TLR2, ELA2, H2AC4; H2AC8, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF1, NCF4, FPR1, AQP9, MAPK14 | More | | | Phenindamine | hsa04622 | RIG-I-like receptor signaling pathway | 2.47E-02 | 1 | Q12933 | TRAF2 | More | | | Phenindamine | hsa04623 | Cytosolic DNA-sensing pathway | 3.15E-02 | 2 | P01568, P25963 | IFNA21, NFKBIA | More | | | Phenindamine | hsa04640 | Hematopoietic cell lineage | 1.54E-03 | 9 | P21926, P14778, P27930, P11215, P25063, P07766, P01732, P01730, P09564 | CD9, IL1R1, IL1R2, ITGAM, CD24, CD3E, CD8A, CD4, CD7 | More | | | Phenindamine | hsa04650 | Natural killer cell mediated cytotoxicity | 3.09E-07 | 15 | P16298, P50591, P19174, P01375, P06239, O60880, P20963, P42338, Q02750, Q13241, P26718, O14931, P26717, Q14953, P26715 | PPP3CB, TNFSF10, PLCG1, TNF, LCK, SH2D1A, CD247, PIK3CB, MAP2K1, KLRD1, KLRK1, NCR3, KLRC2, KIR2DS5, KLRC1 | More | | | Phenindamine | hsa04657 | IL-17 signaling pathway | 2.41E-02 | 4 | P19875, P14780, P80188, P01375 | CXCL2, MMP9, LCN2, TNF | More | | | Phenindamine | hsa04658 | Th1 and Th2 cell differentiation | 2.21E-04 | 8 | Q04759, P07766, P20963, P19174, P06239, Q9UL17, P14784, Q13761 | PRKCQ, CD3E, CD247, PLCG1, LCK, TBX21, IL2RB, RUNX3 | More | | | Phenindamine | hsa04659 | Th17 cell differentiation | 1.17E-05 | 12 | P25963, Q04759, P19174, P06239, P14784, P14778, Q9UL17, P84022, Q13485, P08238, P07766, P20963 | NFKBIA, PRKCQ, PLCG1, LCK, IL2RB, IL1R1, TBX21, SMAD3, SMAD4, HSP90AB1, CD3E, CD247 | More | | | Phenindamine | hsa04660 | T cell receptor signaling pathway | 3.37E-03 | 8 | Q04759, P42338, P19174, P07766, P20963, P01732, Q13191, P06239 | PRKCQ, PIK3CB, PLCG1, CD3E, CD247, CD8A, CBLB, LCK | More | | | Phenindamine | hsa04662 | B cell receptor signaling pathway | 1.74E-02 | 5 | P42338, P60033, P07948, P21854, Q8N149 | PIK3CB, CD81, LYN, CD72, LILRA2 | More | | | Phenindamine | hsa04664 | Fc epsilon RI signaling pathway | 2.47E-02 | 4 | P42338, P07948, P19174, P09917 | PIK3CB, LYN, PLCG1, ALOX5 | More | | | Phenindamine | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | | | Phenindamine | hsa04672 | Intestinal immune network for IgA production | 3.76E-03 | 3 | P29965, P10747, P13765 | CD40LG, CD28, HLA-DOB | More | | | Phenindamine | hsa04713 | Circadian entrainment | 2.60E-02 | 4 | P0DP23, P17252, P62873, Q14643 | CALM1, PRKCA, GNB1, ITPR1 | More | | | Phenindamine | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | | Phenindamine | hsa04720 | Long-term potentiation | 1.95E-03 | 6 | P17252, P16298, P0DP23, P51812, Q02750, Q14643 | PRKCA, PPP3CB, CALM1, RPS6KA3, MAP2K1, ITPR1 | More | | | Phenindamine | hsa04721 | Synaptic vesicle cycle | 3.15E-02 | 2 | Q13488, P31645 | TCIRG1, SLC6A4 | More | | | Phenindamine | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | | Phenindamine | hsa04723 | Retrograde endocannabinoid signaling | 1.88E-02 | 4 | Q14643, P17252, P62873, Q16718 | ITPR1, PRKCA, GNB1, NDUFA5 | More | | | Phenindamine | hsa04724 | Glutamatergic synapse | 9.51E-03 | 4 | O15399, P63218, P50151, P15104 | GRIN2D, GNG5, GNG10, GLUL | More | | | Phenindamine | hsa04725 | Cholinergic synapse | 1.88E-02 | 4 | Q14643, P17252, P62873, P10415 | ITPR1, PRKCA, GNB1, BCL2 | More | | | Phenindamine | hsa04727 | GABAergic synapse | 2.33E-02 | 3 | P63218, P50151, P15104 | GNG5, GNG10, GLUL | More | | | Phenindamine | hsa04728 | Dopaminergic synapse | 3.55E-02 | 5 | Q14643, P17252, P62873, Q13362, P0DP23 | ITPR1, PRKCA, GNB1, PPP2R5C, CALM1 | More | | | Phenindamine | hsa04730 | Long-term depression | 3.72E-02 | 2 | Q14344, P07948 | GNA13, LYN | More | | | Phenindamine | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | | | Phenindamine | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | | | Phenindamine | hsa04744 | Phototransduction | 1.02E-02 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | | Phenindamine | hsa04750 | Inflammatory mediator regulation of TRP channels | 7.24E-03 | 5 | P14778, P19174, P42338, P24723, Q04759 | IL1R1, PLCG1, PIK3CB, PRKCH, PRKCQ | More | | | Phenindamine | hsa04912 | GnRH signaling pathway | 3.89E-02 | 3 | P17252, Q14643, P0DP23 | PRKCA, ITPR1, CALM1 | More | | | Phenindamine | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | | Phenindamine | hsa04914 | Progesterone-mediated oocyte maturation | 2.94E-02 | 3 | Q17RY0, P51812, Q02750 | CPEB4, RPS6KA3, MAP2K1 | More | | | Phenindamine | hsa04922 | Glucagon signaling pathway | 3.47E-02 | 4 | Q12778, Q13370, P0DP23, Q14643 | FOXO1, PDE3B, CALM1, ITPR1 | More | | | Phenindamine | hsa04923 | Regulation of lipolysis in adipocytes | 2.24E-02 | 3 | P07550, P42338, Q9Y4H2 | ADRB2, PIK3CB, IRS2 | More | | | Phenindamine | hsa04924 | Renin secretion | 7.38E-04 | 5 | P22694, P07550, Q14643, Q13370, P0DP23 | PRKACB, ADRB2, ITPR1, PDE3B, CALM1 | More | | | Phenindamine | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | | | Phenindamine | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | | | Phenindamine | hsa04930 | Type II diabetes mellitus | 2.47E-02 | 1 | Q02156 | PRKCE | More | | | Phenindamine | hsa04932 | Non-alcoholic fatty liver disease | 2.44E-03 | 5 | P01375, P49841, P48023, Q16718, O14521 | TNF, GSK3B, FASLG, NDUFA5, SDHD | More | | | Phenindamine | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 8.03E-05 | 9 | P84022, Q13485, P42224, P10415, P42338, Q12778, P49767, P17252, P19174 | SMAD3, SMAD4, STAT1, BCL2, PIK3CB, FOXO1, VEGFC, PRKCA, PLCG1 | More | | | Phenindamine | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | | Phenindamine | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | | | Phenindamine | hsa04966 | Collecting duct acid secretion | 2.07E-03 | 3 | Q13488, P00918, Q9Y666 | TCIRG1, CA2, SLC12A7 | More | | | Phenindamine | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | | | Phenindamine | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | | Phenindamine | hsa04974 | Protein digestion and absorption | 2.47E-02 | 1 | Q7Z2H8 | SLC36A1 | More | | | Phenindamine | hsa04975 | Fat digestion and absorption | 3.43E-02 | 1 | O14494 | PLPP1 | More | | | Phenindamine | hsa04976 | Bile secretion | 3.32E-02 | 2 | O43315, P08183 | AQP9, ABCB1 | More | | | Phenindamine | hsa05010 | Alzheimer disease | 4.45E-03 | 13 | Q16718, O14521, Q14643, O15399, Q9NZJ5, P0DP23, Q13564, Q71U36, Q13509, P68371, P09603, P21796, Q08752 | NDUFA5, SDHD, ITPR1, GRIN2D, EIF2AK3, CALM1, APPBP1, TUBA1A, TUBB3, TUBB2C, CSF1, VDAC1, PPID | More | | | Phenindamine | hsa05012 | Parkinson disease | 2.25E-02 | 6 | Q16718, O14521, Q14643, P0DP23, Q13509, P68371 | NDUFA5, SDHD, ITPR1, CALM1, TUBB3, TUBB2C | More | | | Phenindamine | hsa05017 | Spinocerebellar ataxia | 2.43E-02 | 1 | P28074 | PSMB5 | More | | | Phenindamine | hsa05020 | Prion disease | 1.31E-03 | 9 | Q16718, O14521, Q14643, Q13509, P68371, P49841, P14598, Q15080, Q16539 | NDUFA5, SDHD, ITPR1, TUBB3, TUBB2C, GSK3B, NCF1, NCF4, MAPK14 | More | | | Phenindamine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 2.00E-04 | 12 | Q14643, Q13509, P68371, P49841, P10415, Q16718, O14521, Q13561, P17252, Q16539, Q08752, P0DP23 | ITPR1, TUBB3, TUBB2C, GSK3B, BCL2, NDUFA5, SDHD, DCTN2, PRKCA, MAPK14, PPID, CALM1 | More | | | Phenindamine | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | | | Phenindamine | hsa05032 | Morphine addiction | 1.34E-02 | 4 | P63218, P50151, Q07343, P43250 | GNG5, GNG10, PDE4B, GRK6 | More | | | Phenindamine | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | | Phenindamine | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.78E-03 | 5 | P09341, P19875, P19174, P25024, P25025 | CXCL1, CXCL2, PLCG1, CXCR1, CXCR2 | More | | | Phenindamine | hsa05131 | Shigellosis | 3.33E-03 | 10 | Q12933, P68431, Q02156, Q9UDY8, Q14247, Q14643, Q12778, Q13315, P10415, Q08752 | TRAF2, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, PRKCE, MALT1, CTTN, ITPR1, FOXO1, ATM, BCL2, PPID | More | | | Phenindamine | hsa05132 | Salmonella infection | 8.60E-04 | 9 | P25963, Q9UJU2, Q13489, P10415, O60603, Q9BQS8, Q13561, Q13509, P68371 | NFKBIA, LEF1, BIRC3, BCL2, TLR2, FYCO1, DCTN2, TUBB3, TUBB2C | More | | | Phenindamine | hsa05133 | Pertussis | 4.20E-02 | 1 | P0C0L4 | C4A | More | | | Phenindamine | hsa05134 | Legionellosis | 1.29E-02 | 4 | P11215, P11142, P09341, P19875 | ITGAM, HSPA8, CXCL1, CXCL2 | More | | | Phenindamine | hsa05140 | Leishmaniasis | 1.06E-04 | 7 | P14598, P42224, P13765, O60603, P25963, P29350, Q15080 | NCF1, STAT1, HLA-DOB, TLR2, NFKBIA, PTPN6, NCF4 | More | | | Phenindamine | hsa05143 | African trypanosomiasis | 7.50E-04 | 4 | P01375, P69905, P68871, P48023 | TNF, HBA2, HBB, FASLG | More | | | Phenindamine | hsa05144 | Malaria | 1.44E-03 | 5 | P69905, P68871, P01375, P35443, P26718 | HBA2, HBB, TNF, THBS4, KLRK1 | More | | | Phenindamine | hsa05145 | Toxoplasmosis | 1.02E-03 | 7 | P25963, P10415, Q13489, P42224, P13765, O60603, P29965 | NFKBIA, BCL2, BIRC3, STAT1, HLA-DOB, TLR2, CD40LG | More | | | Phenindamine | hsa05146 | Amoebiasis | 2.05E-05 | 11 | P09341, P19875, P14778, P27930, P01375, P42338, P11215, P05089, P30679, P22694, P12814 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, PIK3CB, ITGAM, ARG1, GNA15, PRKACB, ACTN1 | More | | | Phenindamine | hsa05150 | Staphylococcus aureus infection | 1.91E-02 | 4 | Q14532, P59665, P59666, P49913 | KRT32, DEFA1; DEFA1B, DEFA3, CAMP | More | | | Phenindamine | hsa05152 | Tuberculosis | 7.93E-04 | 8 | Q13488, P0DP23, P42224, O60603, P10415, P13765, P01568, Q9UDY8 | TCIRG1, CALM1, STAT1, TLR2, BCL2, HLA-DOB, IFNA21, MALT1 | More | | | Phenindamine | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | | Phenindamine | hsa05161 | Hepatitis B | 8.49E-03 | 4 | P25963, Q13485, P10415, P84022 | NFKBIA, SMAD4, BCL2, SMAD3 | More | | | Phenindamine | hsa05165 | Human papillomavirus infection | 3.10E-02 | 8 | P16144, Q05086, P01568, P42224, Q13488, Q13362, Q12778, Q13315 | ITGB4, UBE3A, IFNA21, STAT1, TCIRG1, PPP2R5C, FOXO1, ATM | More | | | Phenindamine | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 3.04E-03 | 10 | P01568, P42224, P62873, P62879, P16298, Q14643, Q02750, P0DP23, P0CG47, Q9UJU2 | IFNA21, STAT1, GNB1, GNB2, PPP3CB, ITPR1, MAP2K1, CALM1, UBB, LEF1 | More | | | Phenindamine | hsa05168 | Herpes simplex virus 1 infection | 6.00E-04 | 16 | P25963, P01568, Q05823, P42224, Q07955, Q01130, Q13243, Q13489, Q9Y2A4, Q13398, P51522, Q9HCX3, P17038, P52738, O75820, Q9UDV6 | NFKBIA, IFNA21, RNASEL, STAT1, SFRS1, SFRS2, SFRS5, BIRC3, ZNF443, ZNF211, ZNF83, ZNF304, ZNF43, ZNF140, ZNF189, ZNF212 | More | | | Phenindamine | hsa05170 | Human immunodeficiency virus 1 infection | 8.44E-05 | 14 | Q02750, P62873, P62879, P16298, P0DP23, Q05397, P17252, Q14643, P01568, O60603, Q13315, P10415, Q9Y6Q5, P20333 | MAP2K1, GNB1, GNB2, PPP3CB, CALM1, PTK2, PRKCA, ITPR1, IFNA21, TLR2, ATM, BCL2, AP1M2, TNFRSF1B | More | | | Phenindamine | hsa05171 | Coronavirus disease - COVID-19 | 3.87E-04 | 5 | P62249, P40429, P27635, Q07020, P05386 | RPS16, RPL13A, RPL10, RPL18, RPLP1 | More | | | Phenindamine | hsa05200 | Pathways in cancer | 1.55E-03 | 28 | Q13751, P42338, P08238, P42224, P19174, Q9UJU2, P17252, P43246, P84022, Q13485, Q13547, P14923, P30281, P10415, Q13489, P49767, Q12778, P43657, P25116, P62873, P63218, P50151, Q14344, Q7LDG7, O75293, P0DP23, P01568, P14784 | LAMB3, PIK3CB, HSP90AB1, STAT1, PLCG1, LEF1, PRKCA, MSH2, SMAD3, SMAD4, HDAC1, JUP, CCND3, BCL2, BIRC3, VEGFC, FOXO1, P2RY5, F2R, GNB1, GNG5, GNG10, GNA13, RASGRP2, GADD45B, CALM1, IFNA21, IL2RB | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13751 | LAMB3 | Laminin subunit beta-3 | 0.844 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | 0.777 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | -0.823 | | P17252 | PRKCA | Protein kinase C alpha type | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | -0.706 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.766 | | P17252 | PRKCA | Protein kinase C alpha type | Q9UJU2 | LEF1 | Lymphoid enhancer-binding factor 1 | 0.881 | | P17252 | PRKCA | Protein kinase C alpha type | P17252 | PRKCA | Protein kinase C alpha type | 1 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43246 | MSH2 | DNA mismatch repair protein Msh2 | -0.811 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | 0.725 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.746 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13547 | HDAC1 | Histone deacetylase 1 | -0.754 | | P17252 | PRKCA | Protein kinase C alpha type | P14923 | JUP | Junction plakoglobin | 0.761 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P30281 | CCND3 | G1/S-specific cyclin-D3 | 0.743 | | P17252 | PRKCA | Protein kinase C alpha type | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.844 | | P17252 | PRKCA | Protein kinase C alpha type | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | 0.849 | | P17252 | PRKCA | Protein kinase C alpha type | P49767 | VEGFC | Vascular endothelial growth factor C | 0.719 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P49767 | VEGFC | Vascular endothelial growth factor C | 0.743 | | P17252 | PRKCA | Protein kinase C alpha type | Q12778 | FOXO1 | Forkhead box protein O1 | 0.863 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | -0.735 | | P17252 | PRKCA | Protein kinase C alpha type | P25116 | F2R | Proteinase-activated receptor 1 | 0.857 | | P17252 | PRKCA | Protein kinase C alpha type | P62873 | GNB1 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | -0.852 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.941 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.948 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q14344 | GNA13 | Guanine nucleotide-binding protein subunit alpha-13 | 0.87 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q7LDG7 | RASGRP2 | RAS guanyl-releasing protein 2 | 0.704 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | 0.731 | | P17252 | PRKCA | Protein kinase C alpha type | P0DP23 | CALM1 | Calmodulin-1 | -0.776 | | P17252 | PRKCA | Protein kinase C alpha type | P01568 | IFNA21 | Interferon alpha-21 | 0.733 | | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.835 |
| | Phenindamine | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | | | Phenindamine | hsa05204 | Chemical carcinogenesis | 1.09E-03 | 3 | P09211, P78417, P11712 | GSTP1, GSTO1, CYP2C9 | More | | | Phenindamine | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | | | Phenindamine | hsa05210 | Colorectal cancer | 1.78E-02 | 3 | P84022, Q13485, P10415 | SMAD3, SMAD4, BCL2 | More | | | Phenindamine | hsa05212 | Pancreatic cancer | 4.45E-03 | 4 | P42338, P84022, Q13485, O75293 | PIK3CB, SMAD3, SMAD4, GADD45B | More | | | Phenindamine | hsa05213 | Endometrial cancer | 3.79E-02 | 2 | O15169, Q02750 | AXIN1, MAP2K1 | More | | | Phenindamine | hsa05216 | Thyroid cancer | 3.80E-02 | 2 | P01106, O75293 | MYC, GADD45B | More | | | Phenindamine | hsa05220 | Chronic myeloid leukemia | 1.44E-03 | 6 | Q13547, Q13485, P25963, P84022, P42338, O75293 | HDAC1, SMAD4, NFKBIA, SMAD3, PIK3CB, GADD45B | More | | | Phenindamine | hsa05222 | Small cell lung cancer | 1.50E-02 | 3 | Q13489, P10415, P25963 | BIRC3, BCL2, NFKBIA | More | | | Phenindamine | hsa05223 | Non-small cell lung cancer | 1.39E-02 | 3 | P10826, Q9HC35, O75293 | RARB, EML4, GADD45B | More | | | Phenindamine | hsa05226 | Gastric cancer | 4.33E-03 | 5 | Q02750, O15169, P84022, Q13485, P10415 | MAP2K1, AXIN1, SMAD3, SMAD4, BCL2 | More | | | Phenindamine | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 2.99E-04 | 8 | P42338, P19174, P07766, P20963, P06239, Q04759, Q9HC35, P01730 | PIK3CB, PLCG1, CD3E, CD247, LCK, PRKCQ, EML4, CD4 | More | | | Phenindamine | hsa05320 | Autoimmune thyroid disease | 1.27E-03 | 4 | P13765, P29965, P01568, P10747 | HLA-DOB, CD40LG, IFNA21, CD28 | More | | | Phenindamine | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | | | Phenindamine | hsa05322 | Systemic lupus erythematosus | 4.80E-06 | 10 | P08246, P09871, P10747, P13765, P29965, Q6FI13, Q93077, P62807, O60814, P68431 | ELA2, C1S, CD28, HLA-DOB, CD40LG, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | | Phenindamine | hsa05323 | Rheumatoid arthritis | 1.29E-02 | 4 | P13765, Q13488, P10747, O60603 | HLA-DOB, TCIRG1, CD28, TLR2 | More | | | Phenindamine | hsa05330 | Allograft rejection | 1.04E-03 | 5 | P13765, P29965, P48023, P10747, P01375 | HLA-DOB, CD40LG, FASLG, CD28, TNF | More | | | Phenindamine | hsa05332 | Graft-versus-host disease | 7.27E-04 | 4 | P48023, P01375, P26715, Q13241 | FASLG, TNF, KLRC1, KLRD1 | More | | | Phenindamine | hsa05340 | Primary immunodeficiency | 1.28E-03 | 4 | P01730, P11912, P07766, P06239 | CD4, CD79A, CD3E, LCK | More | | | Phenindamine | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | | | Phenindamine | hsa05415 | Diabetic cardiomyopathy | 5.60E-05 | 8 | P17252, P14598, Q15080, Q16718, O14521, Q16539, P49841, P04406 | PRKCA, NCF1, NCF4, NDUFA5, SDHD, MAPK14, GSK3B, GAPDH | More | | | Phenindamine | hsa05416 | Viral myocarditis | 2.62E-02 | 3 | P13765, P29965, P10747 | HLA-DOB, CD40LG, CD28 | More | |
|
